Which enzyme does miglustat inhibit in substrate reduction therapy for type 1 Gaucher disease?

Miglustat inhibits glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids, providing the rationale for substrate reduction therapy in type 1 Gaucher disease.